Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Eysins, Switzerland

1 abstract

Abstract
A double-blind, randomized, two-arm, single-dose, parallel-group study in healthy participants to compare the pharmacokinetics, pharmacodynamics, and immunogenicity of FKS518 proposed biosimilar to denosumab with the originator (LUMIADE-1 study).
Org: Lake Zurich, IL, MTZ Clinical Research Center, Eysins, Switzerland,